Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study
Summary Background Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2016-06, Vol.16 (6), p.703-711 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 711 |
|---|---|
| container_issue | 6 |
| container_start_page | 703 |
| container_title | The Lancet infectious diseases |
| container_volume | 16 |
| creator | Mackenzie, Grant A, Dr Hill, Philip C, Prof Jeffries, David J, PhD Hossain, Ilias, MPH Uchendu, Uchendu, MD Ameh, David, MPH Ndiaye, Malick, DP Adeyemi, Oyedeji, MBBS Pathirana, Jayani, MSc Olatunji, Yekini, MBChB Abatan, Bade, MBChB Muhammad, Bilquees S, MBBS Fombah, Augustin E, MD Saha, Debasish, PhD Plumb, Ian, MBBS Akano, Aliu, FMCR Ebruke, Bernard, FWACP Ideh, Readon C, FWACP Kuti, Bankole, MBChB Githua, Peter, MSc Olutunde, Emmanuel, MBChB Ofordile, Ogochukwu, MBBS Green, Edward, MBBS Usuf, Effua, PhD Badji, Henry, MSc Ikumapayi, Usman N A, MSc Manjang, Ahmad, MSc Salaudeen, Rasheed, BSc Nsekpong, E David, BSc Jarju, Sheikh, DVM Antonio, Martin, PhD Sambou, Sana, MSc Ceesay, Lamin, MSc Lowe-Jallow, Yamundow, MSc Jasseh, Momodou, PhD Mulholland, Kim, Prof Knoll, Maria, PhD Levine, Orin S, PhD Howie, Stephen R, PhD Adegbola, Richard A, Prof Greenwood, Brian M, Prof Corrah, Tumani, Prof |
| description | Summary Background Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011. Methods We conducted population-based surveillance for invasive pneumococcal disease in individuals aged 2 months and older who were residents of the Basse Health and Demographic Surveillance System (BHDSS) in the Upper River Region, The Gambia, using standardised criteria to identify and investigate patients. Surveillance was done between May, 2008, and December, 2014. We compared the incidence of invasive pneumococcal disease between baseline (May 12, 2008–May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013–Dec 31, 2014), adjusting for changes in case ascertainment over time. Findings We investigated 14 650 patients, in whom we identified 320 cases of invasive pneumococcal disease. Compared with baseline, after the introduction of the PCV programme, the incidence of invasive pneumococcal disease decreased by 55% (95% CI 30–71) in the 2–23 months age group, from 253 to 113 per 100 000 population. This decrease was due to an 82% (95% CI 64–91) reduction in serotypes covered by the PCV13 vaccine. In the 2–4 years age group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 25–75), from 113 to 49 cases per 100 000, with a 68% (95% CI 39–83) reduction in PCV13 serotypes. The incidence of non-PCV13 serotypes in children aged 2–59 months increased by 47% (−21 to 275) from 28 to 41 per 100 000, with a broad range of serotypes. The incidence of non-pneumococcal bacteraemia varied little over time. Interpretation The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2–59 months by around 55%. Further surveillance is needed to ascertain the maximum effect of the vaccine in the 2–4 years and older age groups, and to monitor serotype replacement. Low-income and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneumococcal disease. Funding GAVI's Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP), Bill & Melinda Gates Foundation, and the UK Medical Research Council. |
| doi_str_mv | 10.1016/S1473-3099(16)00054-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4909992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1473309916000542</els_id><sourcerecordid>1797540209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c649t-b5fa032e84247ffa26767fc4a31128792e3df37a626e636ad4085dc6b4387c1b3</originalsourceid><addsrcrecordid>eNqFkl9vljAUh4nRuDn9CJom3swLtP9oqRdbzDKnyRIvnNdNKYetr9AiBZL3i_h5LTCn282uKOU5T3sOvyx7TfB7gon48J1wyXKGlTom4h3GuOA5fZIdpm2ec17Ip-t6Qw6yFzHuMCaSYP48O6CiVGlZHGa_z5sG7IhCg8YbQM6PQ6gnO7rgl73ew9QFG6w1LbLB76ZrMwKajbXOm43yqWo20c1wH69dBBMXJ7pK6gvTVc58RAb1oZ_atTivElCjOA0zuLY13gKK41TvX2bPGtNGeHX7PMp-fD6_OvuSX367-Hr26TK3gqsxr4rGYEah5JTLpjFUSCEbyw0jhJZSUWB1w6QRVIBgwtQcl0VtRcVZKS2p2FF2snn7qeqgtpD6N63uB9eZYa-Dcfr-F-9u9HWYNVdprIomwfGtYAi_Joij7ly0sPQCYYqalLiUWFJJHkelkgXHFKuEvn2A7sI0-DSJhVKFlJKzRBUbZYcQ4wDN3b0J1ktI9BoSvSRAp7c1JHq585v_m76r-puKBJxuAKTRzw4GHa2D9HNqN6Sw6Dq4R484eWCwrfMuxeIn7CH-60ZHqvEmWRxErAbK_gDt6ePQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1799577743</pqid></control><display><type>article</type><title>Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Mackenzie, Grant A, Dr ; Hill, Philip C, Prof ; Jeffries, David J, PhD ; Hossain, Ilias, MPH ; Uchendu, Uchendu, MD ; Ameh, David, MPH ; Ndiaye, Malick, DP ; Adeyemi, Oyedeji, MBBS ; Pathirana, Jayani, MSc ; Olatunji, Yekini, MBChB ; Abatan, Bade, MBChB ; Muhammad, Bilquees S, MBBS ; Fombah, Augustin E, MD ; Saha, Debasish, PhD ; Plumb, Ian, MBBS ; Akano, Aliu, FMCR ; Ebruke, Bernard, FWACP ; Ideh, Readon C, FWACP ; Kuti, Bankole, MBChB ; Githua, Peter, MSc ; Olutunde, Emmanuel, MBChB ; Ofordile, Ogochukwu, MBBS ; Green, Edward, MBBS ; Usuf, Effua, PhD ; Badji, Henry, MSc ; Ikumapayi, Usman N A, MSc ; Manjang, Ahmad, MSc ; Salaudeen, Rasheed, BSc ; Nsekpong, E David, BSc ; Jarju, Sheikh, DVM ; Antonio, Martin, PhD ; Sambou, Sana, MSc ; Ceesay, Lamin, MSc ; Lowe-Jallow, Yamundow, MSc ; Jasseh, Momodou, PhD ; Mulholland, Kim, Prof ; Knoll, Maria, PhD ; Levine, Orin S, PhD ; Howie, Stephen R, PhD ; Adegbola, Richard A, Prof ; Greenwood, Brian M, Prof ; Corrah, Tumani, Prof</creator><creatorcontrib>Mackenzie, Grant A, Dr ; Hill, Philip C, Prof ; Jeffries, David J, PhD ; Hossain, Ilias, MPH ; Uchendu, Uchendu, MD ; Ameh, David, MPH ; Ndiaye, Malick, DP ; Adeyemi, Oyedeji, MBBS ; Pathirana, Jayani, MSc ; Olatunji, Yekini, MBChB ; Abatan, Bade, MBChB ; Muhammad, Bilquees S, MBBS ; Fombah, Augustin E, MD ; Saha, Debasish, PhD ; Plumb, Ian, MBBS ; Akano, Aliu, FMCR ; Ebruke, Bernard, FWACP ; Ideh, Readon C, FWACP ; Kuti, Bankole, MBChB ; Githua, Peter, MSc ; Olutunde, Emmanuel, MBChB ; Ofordile, Ogochukwu, MBBS ; Green, Edward, MBBS ; Usuf, Effua, PhD ; Badji, Henry, MSc ; Ikumapayi, Usman N A, MSc ; Manjang, Ahmad, MSc ; Salaudeen, Rasheed, BSc ; Nsekpong, E David, BSc ; Jarju, Sheikh, DVM ; Antonio, Martin, PhD ; Sambou, Sana, MSc ; Ceesay, Lamin, MSc ; Lowe-Jallow, Yamundow, MSc ; Jasseh, Momodou, PhD ; Mulholland, Kim, Prof ; Knoll, Maria, PhD ; Levine, Orin S, PhD ; Howie, Stephen R, PhD ; Adegbola, Richard A, Prof ; Greenwood, Brian M, Prof ; Corrah, Tumani, Prof</creatorcontrib><description>Summary Background Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011. Methods We conducted population-based surveillance for invasive pneumococcal disease in individuals aged 2 months and older who were residents of the Basse Health and Demographic Surveillance System (BHDSS) in the Upper River Region, The Gambia, using standardised criteria to identify and investigate patients. Surveillance was done between May, 2008, and December, 2014. We compared the incidence of invasive pneumococcal disease between baseline (May 12, 2008–May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013–Dec 31, 2014), adjusting for changes in case ascertainment over time. Findings We investigated 14 650 patients, in whom we identified 320 cases of invasive pneumococcal disease. Compared with baseline, after the introduction of the PCV programme, the incidence of invasive pneumococcal disease decreased by 55% (95% CI 30–71) in the 2–23 months age group, from 253 to 113 per 100 000 population. This decrease was due to an 82% (95% CI 64–91) reduction in serotypes covered by the PCV13 vaccine. In the 2–4 years age group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 25–75), from 113 to 49 cases per 100 000, with a 68% (95% CI 39–83) reduction in PCV13 serotypes. The incidence of non-PCV13 serotypes in children aged 2–59 months increased by 47% (−21 to 275) from 28 to 41 per 100 000, with a broad range of serotypes. The incidence of non-pneumococcal bacteraemia varied little over time. Interpretation The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2–59 months by around 55%. Further surveillance is needed to ascertain the maximum effect of the vaccine in the 2–4 years and older age groups, and to monitor serotype replacement. Low-income and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneumococcal disease. Funding GAVI's Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP), Bill & Melinda Gates Foundation, and the UK Medical Research Council.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(16)00054-2</identifier><identifier>PMID: 26897105</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Age groups ; Child, Preschool ; Female ; Gambia ; Health risk assessment ; Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage ; HIV ; Human immunodeficiency virus ; Humans ; Immunization ; Immunologic Factors ; Infant ; Infectious Disease ; Infectious diseases ; Low income areas ; Low income groups ; Male ; Maternal & child health ; Medical research ; Medical Subject Headings-MeSH ; Meningitis ; Mortality ; Pneumococcal Infections - immunology ; Pneumococcal Infections - prevention & control ; Pneumococcal Vaccines - administration & dosage ; Pneumonia ; Population ; Population Surveillance ; Sepsis ; Streptococcus pneumoniae ; Streptococcus pneumoniae - immunology ; Studies ; Vaccination - methods ; Vaccines ; Vaccines, Conjugate - immunology</subject><ispartof>The Lancet infectious diseases, 2016-06, Vol.16 (6), p.703-711</ispartof><rights>Mackenzie et al. Open Access article distributed under the terms of CC BY</rights><rights>2016 Mackenzie et al. Open Access article distributed under the terms of CC BY</rights><rights>Copyright © 2016 Mackenzie et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 01, 2016</rights><rights>2016 Mackenzie et al. Open Access article distributed under the terms of CC BY 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c649t-b5fa032e84247ffa26767fc4a31128792e3df37a626e636ad4085dc6b4387c1b3</citedby><cites>FETCH-LOGICAL-c649t-b5fa032e84247ffa26767fc4a31128792e3df37a626e636ad4085dc6b4387c1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309916000542$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26897105$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mackenzie, Grant A, Dr</creatorcontrib><creatorcontrib>Hill, Philip C, Prof</creatorcontrib><creatorcontrib>Jeffries, David J, PhD</creatorcontrib><creatorcontrib>Hossain, Ilias, MPH</creatorcontrib><creatorcontrib>Uchendu, Uchendu, MD</creatorcontrib><creatorcontrib>Ameh, David, MPH</creatorcontrib><creatorcontrib>Ndiaye, Malick, DP</creatorcontrib><creatorcontrib>Adeyemi, Oyedeji, MBBS</creatorcontrib><creatorcontrib>Pathirana, Jayani, MSc</creatorcontrib><creatorcontrib>Olatunji, Yekini, MBChB</creatorcontrib><creatorcontrib>Abatan, Bade, MBChB</creatorcontrib><creatorcontrib>Muhammad, Bilquees S, MBBS</creatorcontrib><creatorcontrib>Fombah, Augustin E, MD</creatorcontrib><creatorcontrib>Saha, Debasish, PhD</creatorcontrib><creatorcontrib>Plumb, Ian, MBBS</creatorcontrib><creatorcontrib>Akano, Aliu, FMCR</creatorcontrib><creatorcontrib>Ebruke, Bernard, FWACP</creatorcontrib><creatorcontrib>Ideh, Readon C, FWACP</creatorcontrib><creatorcontrib>Kuti, Bankole, MBChB</creatorcontrib><creatorcontrib>Githua, Peter, MSc</creatorcontrib><creatorcontrib>Olutunde, Emmanuel, MBChB</creatorcontrib><creatorcontrib>Ofordile, Ogochukwu, MBBS</creatorcontrib><creatorcontrib>Green, Edward, MBBS</creatorcontrib><creatorcontrib>Usuf, Effua, PhD</creatorcontrib><creatorcontrib>Badji, Henry, MSc</creatorcontrib><creatorcontrib>Ikumapayi, Usman N A, MSc</creatorcontrib><creatorcontrib>Manjang, Ahmad, MSc</creatorcontrib><creatorcontrib>Salaudeen, Rasheed, BSc</creatorcontrib><creatorcontrib>Nsekpong, E David, BSc</creatorcontrib><creatorcontrib>Jarju, Sheikh, DVM</creatorcontrib><creatorcontrib>Antonio, Martin, PhD</creatorcontrib><creatorcontrib>Sambou, Sana, MSc</creatorcontrib><creatorcontrib>Ceesay, Lamin, MSc</creatorcontrib><creatorcontrib>Lowe-Jallow, Yamundow, MSc</creatorcontrib><creatorcontrib>Jasseh, Momodou, PhD</creatorcontrib><creatorcontrib>Mulholland, Kim, Prof</creatorcontrib><creatorcontrib>Knoll, Maria, PhD</creatorcontrib><creatorcontrib>Levine, Orin S, PhD</creatorcontrib><creatorcontrib>Howie, Stephen R, PhD</creatorcontrib><creatorcontrib>Adegbola, Richard A, Prof</creatorcontrib><creatorcontrib>Greenwood, Brian M, Prof</creatorcontrib><creatorcontrib>Corrah, Tumani, Prof</creatorcontrib><title>Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Summary Background Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011. Methods We conducted population-based surveillance for invasive pneumococcal disease in individuals aged 2 months and older who were residents of the Basse Health and Demographic Surveillance System (BHDSS) in the Upper River Region, The Gambia, using standardised criteria to identify and investigate patients. Surveillance was done between May, 2008, and December, 2014. We compared the incidence of invasive pneumococcal disease between baseline (May 12, 2008–May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013–Dec 31, 2014), adjusting for changes in case ascertainment over time. Findings We investigated 14 650 patients, in whom we identified 320 cases of invasive pneumococcal disease. Compared with baseline, after the introduction of the PCV programme, the incidence of invasive pneumococcal disease decreased by 55% (95% CI 30–71) in the 2–23 months age group, from 253 to 113 per 100 000 population. This decrease was due to an 82% (95% CI 64–91) reduction in serotypes covered by the PCV13 vaccine. In the 2–4 years age group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 25–75), from 113 to 49 cases per 100 000, with a 68% (95% CI 39–83) reduction in PCV13 serotypes. The incidence of non-PCV13 serotypes in children aged 2–59 months increased by 47% (−21 to 275) from 28 to 41 per 100 000, with a broad range of serotypes. The incidence of non-pneumococcal bacteraemia varied little over time. Interpretation The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2–59 months by around 55%. Further surveillance is needed to ascertain the maximum effect of the vaccine in the 2–4 years and older age groups, and to monitor serotype replacement. Low-income and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneumococcal disease. Funding GAVI's Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP), Bill & Melinda Gates Foundation, and the UK Medical Research Council.</description><subject>Age groups</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Gambia</subject><subject>Health risk assessment</subject><subject>Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunologic Factors</subject><subject>Infant</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Low income areas</subject><subject>Low income groups</subject><subject>Male</subject><subject>Maternal & child health</subject><subject>Medical research</subject><subject>Medical Subject Headings-MeSH</subject><subject>Meningitis</subject><subject>Mortality</subject><subject>Pneumococcal Infections - immunology</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal Vaccines - administration & dosage</subject><subject>Pneumonia</subject><subject>Population</subject><subject>Population Surveillance</subject><subject>Sepsis</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pneumoniae - immunology</subject><subject>Studies</subject><subject>Vaccination - methods</subject><subject>Vaccines</subject><subject>Vaccines, Conjugate - immunology</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkl9vljAUh4nRuDn9CJom3swLtP9oqRdbzDKnyRIvnNdNKYetr9AiBZL3i_h5LTCn282uKOU5T3sOvyx7TfB7gon48J1wyXKGlTom4h3GuOA5fZIdpm2ec17Ip-t6Qw6yFzHuMCaSYP48O6CiVGlZHGa_z5sG7IhCg8YbQM6PQ6gnO7rgl73ew9QFG6w1LbLB76ZrMwKajbXOm43yqWo20c1wH69dBBMXJ7pK6gvTVc58RAb1oZ_atTivElCjOA0zuLY13gKK41TvX2bPGtNGeHX7PMp-fD6_OvuSX367-Hr26TK3gqsxr4rGYEah5JTLpjFUSCEbyw0jhJZSUWB1w6QRVIBgwtQcl0VtRcVZKS2p2FF2snn7qeqgtpD6N63uB9eZYa-Dcfr-F-9u9HWYNVdprIomwfGtYAi_Joij7ly0sPQCYYqalLiUWFJJHkelkgXHFKuEvn2A7sI0-DSJhVKFlJKzRBUbZYcQ4wDN3b0J1ktI9BoSvSRAp7c1JHq585v_m76r-puKBJxuAKTRzw4GHa2D9HNqN6Sw6Dq4R484eWCwrfMuxeIn7CH-60ZHqvEmWRxErAbK_gDt6ePQ</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Mackenzie, Grant A, Dr</creator><creator>Hill, Philip C, Prof</creator><creator>Jeffries, David J, PhD</creator><creator>Hossain, Ilias, MPH</creator><creator>Uchendu, Uchendu, MD</creator><creator>Ameh, David, MPH</creator><creator>Ndiaye, Malick, DP</creator><creator>Adeyemi, Oyedeji, MBBS</creator><creator>Pathirana, Jayani, MSc</creator><creator>Olatunji, Yekini, MBChB</creator><creator>Abatan, Bade, MBChB</creator><creator>Muhammad, Bilquees S, MBBS</creator><creator>Fombah, Augustin E, MD</creator><creator>Saha, Debasish, PhD</creator><creator>Plumb, Ian, MBBS</creator><creator>Akano, Aliu, FMCR</creator><creator>Ebruke, Bernard, FWACP</creator><creator>Ideh, Readon C, FWACP</creator><creator>Kuti, Bankole, MBChB</creator><creator>Githua, Peter, MSc</creator><creator>Olutunde, Emmanuel, MBChB</creator><creator>Ofordile, Ogochukwu, MBBS</creator><creator>Green, Edward, MBBS</creator><creator>Usuf, Effua, PhD</creator><creator>Badji, Henry, MSc</creator><creator>Ikumapayi, Usman N A, MSc</creator><creator>Manjang, Ahmad, MSc</creator><creator>Salaudeen, Rasheed, BSc</creator><creator>Nsekpong, E David, BSc</creator><creator>Jarju, Sheikh, DVM</creator><creator>Antonio, Martin, PhD</creator><creator>Sambou, Sana, MSc</creator><creator>Ceesay, Lamin, MSc</creator><creator>Lowe-Jallow, Yamundow, MSc</creator><creator>Jasseh, Momodou, PhD</creator><creator>Mulholland, Kim, Prof</creator><creator>Knoll, Maria, PhD</creator><creator>Levine, Orin S, PhD</creator><creator>Howie, Stephen R, PhD</creator><creator>Adegbola, Richard A, Prof</creator><creator>Greenwood, Brian M, Prof</creator><creator>Corrah, Tumani, Prof</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier Science ;, The Lancet Pub. Group</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160601</creationdate><title>Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study</title><author>Mackenzie, Grant A, Dr ; Hill, Philip C, Prof ; Jeffries, David J, PhD ; Hossain, Ilias, MPH ; Uchendu, Uchendu, MD ; Ameh, David, MPH ; Ndiaye, Malick, DP ; Adeyemi, Oyedeji, MBBS ; Pathirana, Jayani, MSc ; Olatunji, Yekini, MBChB ; Abatan, Bade, MBChB ; Muhammad, Bilquees S, MBBS ; Fombah, Augustin E, MD ; Saha, Debasish, PhD ; Plumb, Ian, MBBS ; Akano, Aliu, FMCR ; Ebruke, Bernard, FWACP ; Ideh, Readon C, FWACP ; Kuti, Bankole, MBChB ; Githua, Peter, MSc ; Olutunde, Emmanuel, MBChB ; Ofordile, Ogochukwu, MBBS ; Green, Edward, MBBS ; Usuf, Effua, PhD ; Badji, Henry, MSc ; Ikumapayi, Usman N A, MSc ; Manjang, Ahmad, MSc ; Salaudeen, Rasheed, BSc ; Nsekpong, E David, BSc ; Jarju, Sheikh, DVM ; Antonio, Martin, PhD ; Sambou, Sana, MSc ; Ceesay, Lamin, MSc ; Lowe-Jallow, Yamundow, MSc ; Jasseh, Momodou, PhD ; Mulholland, Kim, Prof ; Knoll, Maria, PhD ; Levine, Orin S, PhD ; Howie, Stephen R, PhD ; Adegbola, Richard A, Prof ; Greenwood, Brian M, Prof ; Corrah, Tumani, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c649t-b5fa032e84247ffa26767fc4a31128792e3df37a626e636ad4085dc6b4387c1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Age groups</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Gambia</topic><topic>Health risk assessment</topic><topic>Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunologic Factors</topic><topic>Infant</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Low income areas</topic><topic>Low income groups</topic><topic>Male</topic><topic>Maternal & child health</topic><topic>Medical research</topic><topic>Medical Subject Headings-MeSH</topic><topic>Meningitis</topic><topic>Mortality</topic><topic>Pneumococcal Infections - immunology</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal Vaccines - administration & dosage</topic><topic>Pneumonia</topic><topic>Population</topic><topic>Population Surveillance</topic><topic>Sepsis</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pneumoniae - immunology</topic><topic>Studies</topic><topic>Vaccination - methods</topic><topic>Vaccines</topic><topic>Vaccines, Conjugate - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mackenzie, Grant A, Dr</creatorcontrib><creatorcontrib>Hill, Philip C, Prof</creatorcontrib><creatorcontrib>Jeffries, David J, PhD</creatorcontrib><creatorcontrib>Hossain, Ilias, MPH</creatorcontrib><creatorcontrib>Uchendu, Uchendu, MD</creatorcontrib><creatorcontrib>Ameh, David, MPH</creatorcontrib><creatorcontrib>Ndiaye, Malick, DP</creatorcontrib><creatorcontrib>Adeyemi, Oyedeji, MBBS</creatorcontrib><creatorcontrib>Pathirana, Jayani, MSc</creatorcontrib><creatorcontrib>Olatunji, Yekini, MBChB</creatorcontrib><creatorcontrib>Abatan, Bade, MBChB</creatorcontrib><creatorcontrib>Muhammad, Bilquees S, MBBS</creatorcontrib><creatorcontrib>Fombah, Augustin E, MD</creatorcontrib><creatorcontrib>Saha, Debasish, PhD</creatorcontrib><creatorcontrib>Plumb, Ian, MBBS</creatorcontrib><creatorcontrib>Akano, Aliu, FMCR</creatorcontrib><creatorcontrib>Ebruke, Bernard, FWACP</creatorcontrib><creatorcontrib>Ideh, Readon C, FWACP</creatorcontrib><creatorcontrib>Kuti, Bankole, MBChB</creatorcontrib><creatorcontrib>Githua, Peter, MSc</creatorcontrib><creatorcontrib>Olutunde, Emmanuel, MBChB</creatorcontrib><creatorcontrib>Ofordile, Ogochukwu, MBBS</creatorcontrib><creatorcontrib>Green, Edward, MBBS</creatorcontrib><creatorcontrib>Usuf, Effua, PhD</creatorcontrib><creatorcontrib>Badji, Henry, MSc</creatorcontrib><creatorcontrib>Ikumapayi, Usman N A, MSc</creatorcontrib><creatorcontrib>Manjang, Ahmad, MSc</creatorcontrib><creatorcontrib>Salaudeen, Rasheed, BSc</creatorcontrib><creatorcontrib>Nsekpong, E David, BSc</creatorcontrib><creatorcontrib>Jarju, Sheikh, DVM</creatorcontrib><creatorcontrib>Antonio, Martin, PhD</creatorcontrib><creatorcontrib>Sambou, Sana, MSc</creatorcontrib><creatorcontrib>Ceesay, Lamin, MSc</creatorcontrib><creatorcontrib>Lowe-Jallow, Yamundow, MSc</creatorcontrib><creatorcontrib>Jasseh, Momodou, PhD</creatorcontrib><creatorcontrib>Mulholland, Kim, Prof</creatorcontrib><creatorcontrib>Knoll, Maria, PhD</creatorcontrib><creatorcontrib>Levine, Orin S, PhD</creatorcontrib><creatorcontrib>Howie, Stephen R, PhD</creatorcontrib><creatorcontrib>Adegbola, Richard A, Prof</creatorcontrib><creatorcontrib>Greenwood, Brian M, Prof</creatorcontrib><creatorcontrib>Corrah, Tumani, Prof</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mackenzie, Grant A, Dr</au><au>Hill, Philip C, Prof</au><au>Jeffries, David J, PhD</au><au>Hossain, Ilias, MPH</au><au>Uchendu, Uchendu, MD</au><au>Ameh, David, MPH</au><au>Ndiaye, Malick, DP</au><au>Adeyemi, Oyedeji, MBBS</au><au>Pathirana, Jayani, MSc</au><au>Olatunji, Yekini, MBChB</au><au>Abatan, Bade, MBChB</au><au>Muhammad, Bilquees S, MBBS</au><au>Fombah, Augustin E, MD</au><au>Saha, Debasish, PhD</au><au>Plumb, Ian, MBBS</au><au>Akano, Aliu, FMCR</au><au>Ebruke, Bernard, FWACP</au><au>Ideh, Readon C, FWACP</au><au>Kuti, Bankole, MBChB</au><au>Githua, Peter, MSc</au><au>Olutunde, Emmanuel, MBChB</au><au>Ofordile, Ogochukwu, MBBS</au><au>Green, Edward, MBBS</au><au>Usuf, Effua, PhD</au><au>Badji, Henry, MSc</au><au>Ikumapayi, Usman N A, MSc</au><au>Manjang, Ahmad, MSc</au><au>Salaudeen, Rasheed, BSc</au><au>Nsekpong, E David, BSc</au><au>Jarju, Sheikh, DVM</au><au>Antonio, Martin, PhD</au><au>Sambou, Sana, MSc</au><au>Ceesay, Lamin, MSc</au><au>Lowe-Jallow, Yamundow, MSc</au><au>Jasseh, Momodou, PhD</au><au>Mulholland, Kim, Prof</au><au>Knoll, Maria, PhD</au><au>Levine, Orin S, PhD</au><au>Howie, Stephen R, PhD</au><au>Adegbola, Richard A, Prof</au><au>Greenwood, Brian M, Prof</au><au>Corrah, Tumani, Prof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>16</volume><issue>6</issue><spage>703</spage><epage>711</epage><pages>703-711</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Summary Background Little information is available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries. We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011. Methods We conducted population-based surveillance for invasive pneumococcal disease in individuals aged 2 months and older who were residents of the Basse Health and Demographic Surveillance System (BHDSS) in the Upper River Region, The Gambia, using standardised criteria to identify and investigate patients. Surveillance was done between May, 2008, and December, 2014. We compared the incidence of invasive pneumococcal disease between baseline (May 12, 2008–May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013–Dec 31, 2014), adjusting for changes in case ascertainment over time. Findings We investigated 14 650 patients, in whom we identified 320 cases of invasive pneumococcal disease. Compared with baseline, after the introduction of the PCV programme, the incidence of invasive pneumococcal disease decreased by 55% (95% CI 30–71) in the 2–23 months age group, from 253 to 113 per 100 000 population. This decrease was due to an 82% (95% CI 64–91) reduction in serotypes covered by the PCV13 vaccine. In the 2–4 years age group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 25–75), from 113 to 49 cases per 100 000, with a 68% (95% CI 39–83) reduction in PCV13 serotypes. The incidence of non-PCV13 serotypes in children aged 2–59 months increased by 47% (−21 to 275) from 28 to 41 per 100 000, with a broad range of serotypes. The incidence of non-pneumococcal bacteraemia varied little over time. Interpretation The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2–59 months by around 55%. Further surveillance is needed to ascertain the maximum effect of the vaccine in the 2–4 years and older age groups, and to monitor serotype replacement. Low-income and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneumococcal disease. Funding GAVI's Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP), Bill & Melinda Gates Foundation, and the UK Medical Research Council.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>26897105</pmid><doi>10.1016/S1473-3099(16)00054-2</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2016-06, Vol.16 (6), p.703-711 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4909992 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Age groups Child, Preschool Female Gambia Health risk assessment Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage HIV Human immunodeficiency virus Humans Immunization Immunologic Factors Infant Infectious Disease Infectious diseases Low income areas Low income groups Male Maternal & child health Medical research Medical Subject Headings-MeSH Meningitis Mortality Pneumococcal Infections - immunology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumonia Population Population Surveillance Sepsis Streptococcus pneumoniae Streptococcus pneumoniae - immunology Studies Vaccination - methods Vaccines Vaccines, Conjugate - immunology |
| title | Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T13%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20the%20introduction%20of%20pneumococcal%20conjugate%20vaccination%20on%20invasive%20pneumococcal%20disease%20in%20The%20Gambia:%20a%20population-based%20surveillance%20study&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Mackenzie,%20Grant%20A,%20Dr&rft.date=2016-06-01&rft.volume=16&rft.issue=6&rft.spage=703&rft.epage=711&rft.pages=703-711&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(16)00054-2&rft_dat=%3Cproquest_pubme%3E1797540209%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1799577743&rft_id=info:pmid/26897105&rft_els_id=1_s2_0_S1473309916000542&rfr_iscdi=true |